LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Heron Therapeutics Inc

Fechado

SetorSaúde

1.29 -1.53

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.29

Máximo

1.34

Indicadores-chave

By Trading Economics

Rendimento

-5M

-2.4M

Vendas

-1.7M

37M

Margem de lucro

-6.401

Funcionários

122

EBITDA

-5.3M

-1.6M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+246.15% upside

Dividendos

By Dow Jones

Próximos Ganhos

11 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-60M

207M

Abertura anterior

2.82

Fecho anterior

1.29

Sentimento de Notícias

By Acuity

50%

50%

173 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Heron Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de set. de 2025, 23:59 UTC

Aquisições, Fusões, Aquisições de Empresas

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 de set. de 2025, 22:02 UTC

Grandes Movimentos do Mercado

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 de set. de 2025, 17:01 UTC

Grandes Movimentos do Mercado

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 de set. de 2025, 17:01 UTC

Grandes Movimentos do Mercado

Tron Shares Rise After New Investment From Bravemorning

8 de set. de 2025, 16:14 UTC

Grandes Movimentos do Mercado

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 de set. de 2025, 16:13 UTC

Grandes Movimentos do Mercado

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 de set. de 2025, 23:12 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 de set. de 2025, 23:12 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

8 de set. de 2025, 23:12 UTC

Conversa de Mercado

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 de set. de 2025, 22:56 UTC

Conversa de Mercado

Worst May Be Over for New Zealand Retailers -- Market Talk

8 de set. de 2025, 22:23 UTC

Conversa de Mercado

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 de set. de 2025, 21:51 UTC

Conversa de Mercado

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 de set. de 2025, 21:47 UTC

Grandes Movimentos do Mercado

Microsoft Signs $17.4B AI Deal With Nebius

8 de set. de 2025, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 de set. de 2025, 21:20 UTC

Aquisições, Fusões, Aquisições de Empresas

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 de set. de 2025, 21:19 UTC

Aquisições, Fusões, Aquisições de Empresas

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 de set. de 2025, 21:18 UTC

Aquisições, Fusões, Aquisições de Empresas

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 de set. de 2025, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Tech, Media & Telecom Roundup: Market Talk

8 de set. de 2025, 19:33 UTC

Conversa de Mercado

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 de set. de 2025, 19:22 UTC

Conversa de Mercado

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 de set. de 2025, 19:02 UTC

Conversa de Mercado

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 de set. de 2025, 18:24 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 de set. de 2025, 18:24 UTC

Conversa de Mercado

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 de set. de 2025, 17:29 UTC

Conversa de Mercado

Mexican Inflation Seen Little Changed in August -- Market Talk

8 de set. de 2025, 16:59 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 de set. de 2025, 16:36 UTC

Conversa de Mercado

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 de set. de 2025, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

8 de set. de 2025, 16:16 UTC

Ganhos

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 de set. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

8 de set. de 2025, 16:04 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

Comparação entre Pares

Variação de preço

Heron Therapeutics Inc Previsão

Preço-alvo

By TipRanks

246.15% parte superior

Previsão para 12 meses

Média 4.5 USD  246.15%

Máximo 6 USD

Mínimo 3 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Heron Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

2

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

2.0001 / 2.42Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

173 / 371 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat